Alane Barnes Sells 150,000 Shares of BioCryst Pharmaceuticals (NASDAQ:BCRX) Stock

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) insider Alane Barnes sold 150,000 shares of the firm’s stock in a transaction that occurred on Monday, March 16th. The stock was sold at an average price of $9.15, for a total transaction of $1,372,500.00. Following the sale, the insider owned 400,703 shares of the company’s stock, valued at approximately $3,666,432.45. This represents a 27.24% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link.

BioCryst Pharmaceuticals Stock Performance

BioCryst Pharmaceuticals stock opened at $9.81 on Friday. BioCryst Pharmaceuticals, Inc. has a twelve month low of $6.00 and a twelve month high of $11.31. The firm has a market cap of $2.46 billion, a PE ratio of 8.18 and a beta of 0.74. The firm’s 50 day moving average price is $7.45 and its two-hundred day moving average price is $7.43.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last issued its earnings results on Thursday, February 26th. The biotechnology company reported $1.12 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.07 by $1.05. BioCryst Pharmaceuticals had a net margin of 30.16% and a negative return on equity of 84.33%. The company had revenue of $163.28 million during the quarter, compared to analyst estimates of $151.32 million. During the same quarter last year, the business posted ($0.13) EPS. The company’s revenue for the quarter was up 209.1% on a year-over-year basis. Equities analysts anticipate that BioCryst Pharmaceuticals, Inc. will post -0.36 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several research analysts have weighed in on the company. HC Wainwright upped their target price on BioCryst Pharmaceuticals from $30.00 to $32.00 and gave the stock a “buy” rating in a research report on Monday, December 15th. Evercore began coverage on BioCryst Pharmaceuticals in a report on Wednesday, February 18th. They set an “outperform” rating and a $17.00 price target for the company. Weiss Ratings raised BioCryst Pharmaceuticals from a “sell (d-)” rating to a “hold (c)” rating in a research note on Wednesday, March 4th. Finally, Royal Bank Of Canada dropped their price objective on BioCryst Pharmaceuticals from $14.00 to $13.00 and set an “outperform” rating on the stock in a report on Friday, January 30th. Ten research analysts have rated the stock with a Buy rating and three have given a Hold rating to the company. According to data from MarketBeat, BioCryst Pharmaceuticals presently has a consensus rating of “Moderate Buy” and an average target price of $19.64.

Hedge Funds Weigh In On BioCryst Pharmaceuticals

Several hedge funds have recently bought and sold shares of BCRX. Royal Bank of Canada grew its holdings in BioCryst Pharmaceuticals by 2.4% during the first quarter. Royal Bank of Canada now owns 63,463 shares of the biotechnology company’s stock valued at $476,000 after purchasing an additional 1,458 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its position in shares of BioCryst Pharmaceuticals by 6.7% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 135,314 shares of the biotechnology company’s stock valued at $1,019,000 after purchasing an additional 8,517 shares during the period. Goldman Sachs Group Inc. lifted its stake in shares of BioCryst Pharmaceuticals by 49.6% in the first quarter. Goldman Sachs Group Inc. now owns 1,931,934 shares of the biotechnology company’s stock worth $14,490,000 after buying an additional 640,704 shares during the last quarter. Caxton Associates LLP acquired a new stake in shares of BioCryst Pharmaceuticals in the first quarter worth $314,000. Finally, UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its holdings in shares of BioCryst Pharmaceuticals by 11.8% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 448,466 shares of the biotechnology company’s stock worth $3,363,000 after buying an additional 47,355 shares during the period. 85.88% of the stock is owned by institutional investors and hedge funds.

BioCryst Pharmaceuticals Company Profile

BioCryst Pharmaceuticals, Inc is a clinical‐stage biotechnology company headquartered in Durham, North Carolina, that focuses on the discovery and development of novel, oral small‐molecule medicines for rare and serious diseases. Since its founding in 1986, the company has leveraged structure‐based drug design to advance a pipeline of targeted therapeutics designed to address underlying disease mechanisms rather than just treat symptoms.

The company’s first commercial product, Orladeyo (berotralstat), is an oral kallikrein inhibitor approved for the prophylactic treatment of hereditary angioedema (HAE) in both the United States and Europe.